BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34363937)

  • 41. Design, Synthesis and Antitumor Activities of Novel Quinazolinone Derivatives as Potential EGFR Inhibitors.
    Wang J; Huang L; Chen X; Yuan Y; Sun J; Yang M
    Chem Pharm Bull (Tokyo); 2022; 70(9):637-641. PubMed ID: 36047235
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Azole-hydrazone derivatives: Design, synthesis, in vitro biological evaluation, dual EGFR/HER2 inhibitory activity, cell cycle analysis and molecular docking study as anticancer agents.
    Labib MB; Philoppes JN; Lamie PF; Ahmed ER
    Bioorg Chem; 2018 Feb; 76():67-80. PubMed ID: 29153588
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis, antitumor testing and molecular modeling study of some new 6-substituted amido, azo or thioureido-quinazolin-4(3H)-ones.
    Sabry MA; Ewida HA; Hassan GS; Ghaly MA; El-Subbagh HI
    Bioorg Chem; 2019 Jul; 88():102923. PubMed ID: 30991189
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Benzoxazole-appended piperidine derivatives as novel anticancer candidates against breast cancer.
    AboulWafa OM; Daabees HMG; El-Said AH
    Bioorg Chem; 2023 May; 134():106437. PubMed ID: 36842320
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
    Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA
    Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis, anticancer evaluation and molecular docking studies of new heterocycles linked to sulfonamide moiety as novel human topoisomerase types I and II poisons.
    Halawa AH; Elgammal WE; Hassan SM; Hassan AH; Nassar HS; Ebrahim HY; Mehany ABM; El-Agrody AM
    Bioorg Chem; 2020 May; 98():103725. PubMed ID: 32199303
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biological evaluation, radiosensitizing activity and structural insights of novel halogenated quinazoline-sulfonamide conjugates as selective human carbonic anhydrases IX/XII inhibitors.
    Ghorab MM; Soliman AM; Bua S; Supuran CT
    Bioorg Chem; 2021 Feb; 107():104618. PubMed ID: 33485104
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: Design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR/Topo-1 inhibition.
    Halim PA; Sharkawi SMZ; Labib MB
    Bioorg Chem; 2023 Feb; 131():106273. PubMed ID: 36444790
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inclusion of a 5-fluorouracil moiety in nitrogenous bases derivatives as human carbonic anhydrase IX and XII inhibitors produced a targeted action against MDA-MB-231 and T47D breast cancer cells.
    Petreni A; Bonardi A; Lomelino C; Osman SM; ALOthman ZA; Eldehna WM; El-Haggar R; McKenna R; Nocentini A; Supuran CT
    Eur J Med Chem; 2020 Mar; 190():112112. PubMed ID: 32044580
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular docking studies, biological evaluation and synthesis of novel 3-mercapto-1,2,4-triazole derivatives.
    Ghanaat J; Khalilzadeh MA; Zareyee D
    Mol Divers; 2021 Feb; 25(1):223-232. PubMed ID: 32067134
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation.
    Warda ET; Shehata IA; El-Ashmawy MB; El-Gohary NS
    Bioorg Med Chem; 2020 Nov; 28(21):115674. PubMed ID: 33065442
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design, Synthesis and Anticancer Evaluation of New Substituted Thiophene-Quinoline Derivatives.
    Othman DIA; Selim KB; El-Sayed MA; Tantawy AS; Amen Y; Shimizu K; Okauchi T; Kitamura M
    Bioorg Med Chem; 2019 Oct; 27(19):115026. PubMed ID: 31416740
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of pyridazine derivatives as potential EGFR inhibitors and apoptosis inducers: Design, synthesis, anticancer evaluation, and molecular modeling studies.
    Ahmed MF; Santali EY; Mohi El-Deen EM; Naguib IA; El-Haggar R
    Bioorg Chem; 2021 Jan; 106():104473. PubMed ID: 33243490
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
    Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
    Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pyridazino[1,6-b]quinazolinones as new anticancer scaffold: Synthesis, DNA intercalation, topoisomerase I inhibition and antitumor evaluation in vitro and in vivo.
    Huang WY; Zhang XR; Lyu L; Wang SQ; Zhang XT
    Bioorg Chem; 2020 Jun; 99():103814. PubMed ID: 32278208
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design and Synthesis of Novel Quinazolinone-Based Oxobutanenitrile Derivatives as Antiproliferative Agents Targeting Human Breast Cancer.
    AboulWafa OM; Daabees HMGE; Ezz-ElDien ES
    Anticancer Agents Med Chem; 2022; 22(12):2310-2326. PubMed ID: 34906060
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel quinazolin-4(3H)-one linked to 1,2,3-triazoles: Synthesis and anticancer activity.
    Safavi M; Ashtari A; Khalili F; Mirfazli SS; Saeedi M; Ardestani SK; Rashidi Ranjbar P; Barazandeh Tehrani M; Larijani B; Mahdavi M
    Chem Biol Drug Des; 2018 Jul; 92(1):1373-1381. PubMed ID: 29637699
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD.
    Mir SA; Dash GC; Meher RK; Mohanta PP; Chopdar KS; Mohapatra PK; Baitharu I; Behera AK; Raval MK; Nayak B
    Appl Biochem Biotechnol; 2022 Oct; 194(10):4292-4318. PubMed ID: 35366187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents.
    Philoppes JN; Lamie PF
    Bioorg Chem; 2019 Aug; 89():102978. PubMed ID: 31136900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.